Guillem is a Partner at Ysios Capital with over 15 years of experience in venture capital, specializing in life sciences. He has been involved in several successful investments across Europe and the U.S., including Reviral (acquired by Pfizer), Axonics Modulation (acquired by Boston Scientific), Sanifit (acquired by Vifor), and Verona Pharma (NASDAQ: VRNA).

Earlier in his career, he worked at the Edmond de Rothschild Group in Paris (now Andera Partners), where he contributed to several cross-border investments in the biopharmaceutical sector.

He holds degrees in Biotechnology from the Universitat Autònoma de Barcelona and in Business Administration from the Universitat Pompeu Fabra, and is a CFA charterholder.

In addition to his role on the Board of ReproNovo, Guillem also serves on the Board of VarmX and is a Board Observer at Engrail Therapeutics.